nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Ezetimibe—atherosclerosis	0.234	0.352	CbGbCtD
Raltegravir—UGT1A1—Simvastatin—atherosclerosis	0.217	0.328	CbGbCtD
Raltegravir—UGT1A1—Lovastatin—atherosclerosis	0.213	0.321	CbGbCtD
Raltegravir—UGT1A1—Irinotecan Pathway—NPC1—atherosclerosis	0.00772	0.0664	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL4—atherosclerosis	0.00431	0.0371	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CX3CR1—atherosclerosis	0.00369	0.0317	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CX3CL1—atherosclerosis	0.00362	0.0311	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CX3CR1—atherosclerosis	0.00295	0.0254	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL3—atherosclerosis	0.00295	0.0254	CbGpPWpGaD
Raltegravir—CCR1—connective tissue—atherosclerosis	0.00278	0.294	CbGeAlD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR2—atherosclerosis	0.00267	0.0229	CbGpPWpGaD
Raltegravir—UGT1A1—Heme degradation—HMOX1—atherosclerosis	0.00254	0.0218	CbGpPWpGaD
Raltegravir—CCR1—cardiovascular system—atherosclerosis	0.00242	0.256	CbGeAlD
Raltegravir—CCR1—adipose tissue—atherosclerosis	0.00213	0.226	CbGeAlD
Raltegravir—CCR1—Peptide GPCRs—CCR2—atherosclerosis	0.00213	0.0183	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—EDNRA—atherosclerosis	0.00213	0.0183	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL5—atherosclerosis	0.00191	0.0164	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—AGTR1—atherosclerosis	0.00181	0.0156	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—HRH1—atherosclerosis	0.00176	0.0151	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL4—atherosclerosis	0.00162	0.014	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00151	0.013	CbGpPWpGaD
Raltegravir—CCR1—liver—atherosclerosis	0.0015	0.158	CbGeAlD
Raltegravir—CCR1—Peptide ligand-binding receptors—UTS2—atherosclerosis	0.00145	0.0124	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CX3CR1—atherosclerosis	0.00139	0.0119	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CX3CL1—atherosclerosis	0.00136	0.0117	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL2—atherosclerosis	0.00131	0.0113	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CASR—atherosclerosis	0.00117	0.0101	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—HRH1—atherosclerosis	0.00115	0.00987	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL3—atherosclerosis	0.00111	0.00954	CbGpPWpGaD
Raltegravir—UGT1A1—Porphyrin metabolism—HMOX1—atherosclerosis	0.0011	0.00949	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00109	0.00937	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CNR2—atherosclerosis	0.00109	0.00936	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CX3CR1—atherosclerosis	0.00109	0.00934	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—atherosclerosis	0.00104	0.00893	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CNR2—atherosclerosis	0.00101	0.00869	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—EDNRA—atherosclerosis	0.001	0.00863	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR2—atherosclerosis	0.001	0.00863	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—GSTM1—atherosclerosis	0.000982	0.00844	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—GHRL—atherosclerosis	0.000978	0.00841	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.000971	0.00835	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.000931	0.00801	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.000913	0.00785	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.000865	0.00744	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—atherosclerosis	0.000858	0.00738	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.000858	0.00738	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGTR1—atherosclerosis	0.000853	0.00734	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR2—atherosclerosis	0.000846	0.00728	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL4—atherosclerosis	0.000829	0.00713	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.000785	0.00676	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.000785	0.00676	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.000744	0.0064	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—UTS2—atherosclerosis	0.000739	0.00636	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—KNG1—atherosclerosis	0.000724	0.00623	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.000723	0.00622	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.000717	0.00617	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CX3CR1—atherosclerosis	0.000709	0.0061	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CASR—atherosclerosis	0.000709	0.0061	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CX3CL1—atherosclerosis	0.000695	0.00598	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.000673	0.00579	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.000673	0.00579	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.000668	0.00574	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CNR2—atherosclerosis	0.000659	0.00567	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000656	0.00564	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—HRH1—atherosclerosis	0.000648	0.00558	CbGpPWpGaD
Raltegravir—UGT1A1—liver—atherosclerosis	0.000615	0.0651	CbGeAlD
Raltegravir—CCR1—G alpha (i) signalling events—CCL5—atherosclerosis	0.000605	0.00521	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGT—atherosclerosis	0.0006	0.00516	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRH1—atherosclerosis	0.000589	0.00506	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000576	0.00495	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.000572	0.00492	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL3—atherosclerosis	0.000567	0.00487	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—F2—atherosclerosis	0.000555	0.00477	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR2—atherosclerosis	0.000512	0.00441	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—EDNRA—atherosclerosis	0.000512	0.00441	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—AGT—atherosclerosis	0.000506	0.00436	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GHRL—atherosclerosis	0.000499	0.0043	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.000494	0.00425	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000485	0.00417	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000481	0.00414	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—KNG1—atherosclerosis	0.000438	0.00377	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—AGTR1—atherosclerosis	0.000436	0.00375	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL4—atherosclerosis	0.000426	0.00366	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—UTS2—atherosclerosis	0.000418	0.00359	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000403	0.00346	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CASR—atherosclerosis	0.0004	0.00345	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP7A1—atherosclerosis	0.000391	0.00336	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.000391	0.00336	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000385	0.00332	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—UTS2—atherosclerosis	0.000379	0.00326	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CNR2—atherosclerosis	0.000372	0.0032	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000372	0.0032	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—EDN1—atherosclerosis	0.000369	0.00318	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL5—atherosclerosis	0.000366	0.00315	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CX3CR1—atherosclerosis	0.000364	0.00313	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CASR—atherosclerosis	0.000364	0.00313	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP27A1—atherosclerosis	0.000361	0.00311	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000357	0.00307	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000356	0.00306	CbGpPWpGaD
Raltegravir—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00035	0.00166	CcSEcCtD
Raltegravir—Alopecia—Lovastatin—atherosclerosis	0.00035	0.00166	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HRH1—atherosclerosis	0.000348	0.00299	CbGpPWpGaD
Raltegravir—Myalgia—Rosuvastatin—atherosclerosis	0.000346	0.00164	CcSEcCtD
Raltegravir—Arthralgia—Rosuvastatin—atherosclerosis	0.000346	0.00164	CcSEcCtD
Raltegravir—Alopecia—Ezetimibe—atherosclerosis	0.000343	0.00163	CcSEcCtD
Raltegravir—Mental disorder—Ezetimibe—atherosclerosis	0.00034	0.00161	CcSEcCtD
Raltegravir—Hepatitis—Niacin—atherosclerosis	0.00034	0.00161	CcSEcCtD
Raltegravir—Flatulence—Lovastatin—atherosclerosis	0.00034	0.00161	CcSEcCtD
Raltegravir—Hypoaesthesia—Niacin—atherosclerosis	0.000338	0.00161	CcSEcCtD
Raltegravir—Malnutrition—Ezetimibe—atherosclerosis	0.000338	0.0016	CcSEcCtD
Raltegravir—Erythema—Ezetimibe—atherosclerosis	0.000338	0.0016	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CNR2—atherosclerosis	0.000338	0.00291	CbGpPWpGaD
Raltegravir—Dysgeusia—Lovastatin—atherosclerosis	0.000338	0.0016	CcSEcCtD
Raltegravir—Oedema peripheral—Niacin—atherosclerosis	0.000335	0.00159	CcSEcCtD
Raltegravir—Hepatitis—Pravastatin—atherosclerosis	0.000335	0.00159	CcSEcCtD
Raltegravir—Confusional state—Rosuvastatin—atherosclerosis	0.000335	0.00159	CcSEcCtD
Raltegravir—Back pain—Lovastatin—atherosclerosis	0.000334	0.00158	CcSEcCtD
Raltegravir—Hypoaesthesia—Pravastatin—atherosclerosis	0.000333	0.00158	CcSEcCtD
Raltegravir—Flatulence—Ezetimibe—atherosclerosis	0.000333	0.00158	CcSEcCtD
Raltegravir—Chills—Simvastatin—atherosclerosis	0.000332	0.00158	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000332	0.00285	CbGpPWpGaD
Raltegravir—Infection—Rosuvastatin—atherosclerosis	0.00033	0.00156	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—atherosclerosis	0.00033	0.00284	CbGpPWpGaD
Raltegravir—Visual impairment—Niacin—atherosclerosis	0.000328	0.00155	CcSEcCtD
Raltegravir—Alopecia—Simvastatin—atherosclerosis	0.000327	0.00155	CcSEcCtD
Raltegravir—Back pain—Ezetimibe—atherosclerosis	0.000327	0.00155	CcSEcCtD
Raltegravir—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000326	0.00154	CcSEcCtD
Raltegravir—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000325	0.00154	CcSEcCtD
Raltegravir—Mental disorder—Simvastatin—atherosclerosis	0.000325	0.00154	CcSEcCtD
Raltegravir—Tremor—Lovastatin—atherosclerosis	0.000323	0.00153	CcSEcCtD
Raltegravir—Visual impairment—Pravastatin—atherosclerosis	0.000323	0.00153	CcSEcCtD
Raltegravir—Erythema—Simvastatin—atherosclerosis	0.000323	0.00153	CcSEcCtD
Raltegravir—Ill-defined disorder—Lovastatin—atherosclerosis	0.00032	0.00152	CcSEcCtD
Raltegravir—Eye disorder—Niacin—atherosclerosis	0.000318	0.00151	CcSEcCtD
Raltegravir—Flatulence—Simvastatin—atherosclerosis	0.000318	0.00151	CcSEcCtD
Raltegravir—Tinnitus—Niacin—atherosclerosis	0.000317	0.0015	CcSEcCtD
Raltegravir—Erythema multiforme—Pravastatin—atherosclerosis	0.000317	0.0015	CcSEcCtD
Raltegravir—Dysgeusia—Simvastatin—atherosclerosis	0.000316	0.0015	CcSEcCtD
Raltegravir—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000314	0.00149	CcSEcCtD
Raltegravir—Anaemia—Ezetimibe—atherosclerosis	0.000313	0.00148	CcSEcCtD
Raltegravir—Tinnitus—Pravastatin—atherosclerosis	0.000312	0.00148	CcSEcCtD
Raltegravir—Malaise—Lovastatin—atherosclerosis	0.000311	0.00147	CcSEcCtD
Raltegravir—Cardiac disorder—Pravastatin—atherosclerosis	0.000311	0.00147	CcSEcCtD
Raltegravir—Vertigo—Lovastatin—atherosclerosis	0.00031	0.00147	CcSEcCtD
Raltegravir—Angiopathy—Niacin—atherosclerosis	0.000309	0.00146	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—AGT—atherosclerosis	0.000307	0.00264	CbGpPWpGaD
Raltegravir—Chills—Niacin—atherosclerosis	0.000305	0.00145	CcSEcCtD
Raltegravir—Malaise—Ezetimibe—atherosclerosis	0.000305	0.00145	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000303	0.00143	CcSEcCtD
Raltegravir—Tremor—Simvastatin—atherosclerosis	0.000302	0.00143	CcSEcCtD
Raltegravir—Alopecia—Niacin—atherosclerosis	0.000301	0.00143	CcSEcCtD
Raltegravir—Chills—Pravastatin—atherosclerosis	0.000301	0.00143	CcSEcCtD
Raltegravir—Insomnia—Rosuvastatin—atherosclerosis	0.0003	0.00142	CcSEcCtD
Raltegravir—Ill-defined disorder—Simvastatin—atherosclerosis	0.000299	0.00142	CcSEcCtD
Raltegravir—Palpitations—Ezetimibe—atherosclerosis	0.000299	0.00142	CcSEcCtD
Raltegravir—Paraesthesia—Rosuvastatin—atherosclerosis	0.000298	0.00141	CcSEcCtD
Raltegravir—Anaemia—Simvastatin—atherosclerosis	0.000298	0.00141	CcSEcCtD
Raltegravir—Erythema—Niacin—atherosclerosis	0.000296	0.0014	CcSEcCtD
Raltegravir—Malnutrition—Niacin—atherosclerosis	0.000296	0.0014	CcSEcCtD
Raltegravir—Alopecia—Pravastatin—atherosclerosis	0.000296	0.0014	CcSEcCtD
Raltegravir—Cough—Ezetimibe—atherosclerosis	0.000295	0.0014	CcSEcCtD
Raltegravir—Chest pain—Lovastatin—atherosclerosis	0.000294	0.00139	CcSEcCtD
Raltegravir—Myalgia—Lovastatin—atherosclerosis	0.000294	0.00139	CcSEcCtD
Raltegravir—Arthralgia—Lovastatin—atherosclerosis	0.000294	0.00139	CcSEcCtD
Raltegravir—Anxiety—Lovastatin—atherosclerosis	0.000293	0.00139	CcSEcCtD
Raltegravir—Dyspepsia—Rosuvastatin—atherosclerosis	0.000292	0.00139	CcSEcCtD
Raltegravir—Hypertension—Ezetimibe—atherosclerosis	0.000292	0.00138	CcSEcCtD
Raltegravir—Flatulence—Niacin—atherosclerosis	0.000292	0.00138	CcSEcCtD
Raltegravir—Malaise—Simvastatin—atherosclerosis	0.000291	0.00138	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CCL3—atherosclerosis	0.000291	0.0025	CbGpPWpGaD
Raltegravir—Discomfort—Lovastatin—atherosclerosis	0.00029	0.00138	CcSEcCtD
Raltegravir—Vertigo—Simvastatin—atherosclerosis	0.00029	0.00137	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CCR2—atherosclerosis	0.00029	0.00249	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—EDNRA—atherosclerosis	0.00029	0.00249	CbGpPWpGaD
Raltegravir—Myalgia—Ezetimibe—atherosclerosis	0.000288	0.00137	CcSEcCtD
Raltegravir—Chest pain—Ezetimibe—atherosclerosis	0.000288	0.00137	CcSEcCtD
Raltegravir—Arthralgia—Ezetimibe—atherosclerosis	0.000288	0.00137	CcSEcCtD
Raltegravir—Nervousness—Niacin—atherosclerosis	0.000288	0.00136	CcSEcCtD
Raltegravir—Flatulence—Pravastatin—atherosclerosis	0.000287	0.00136	CcSEcCtD
Raltegravir—Dry mouth—Lovastatin—atherosclerosis	0.000287	0.00136	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000286	0.00136	CcSEcCtD
Raltegravir—Dysgeusia—Pravastatin—atherosclerosis	0.000286	0.00135	CcSEcCtD
Raltegravir—Discomfort—Ezetimibe—atherosclerosis	0.000284	0.00135	CcSEcCtD
Raltegravir—Constipation—Rosuvastatin—atherosclerosis	0.000284	0.00135	CcSEcCtD
Raltegravir—Pain—Rosuvastatin—atherosclerosis	0.000284	0.00135	CcSEcCtD
Raltegravir—Confusional state—Lovastatin—atherosclerosis	0.000284	0.00135	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—F2—atherosclerosis	0.000283	0.00244	CbGpPWpGaD
Raltegravir—Nervousness—Pravastatin—atherosclerosis	0.000283	0.00134	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GHRL—atherosclerosis	0.000282	0.00243	CbGpPWpGaD
Raltegravir—Dry mouth—Ezetimibe—atherosclerosis	0.000282	0.00134	CcSEcCtD
Raltegravir—Infection—Lovastatin—atherosclerosis	0.00028	0.00133	CcSEcCtD
Raltegravir—Confusional state—Ezetimibe—atherosclerosis	0.000278	0.00132	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—atherosclerosis	0.000276	0.00237	CbGpPWpGaD
Raltegravir—Thrombocytopenia—Lovastatin—atherosclerosis	0.000276	0.00131	CcSEcCtD
Raltegravir—Arthralgia—Simvastatin—atherosclerosis	0.000275	0.0013	CcSEcCtD
Raltegravir—Myalgia—Simvastatin—atherosclerosis	0.000275	0.0013	CcSEcCtD
Raltegravir—Chest pain—Simvastatin—atherosclerosis	0.000275	0.0013	CcSEcCtD
Raltegravir—Infection—Ezetimibe—atherosclerosis	0.000274	0.0013	CcSEcCtD
Raltegravir—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000274	0.0013	CcSEcCtD
Raltegravir—Anxiety—Simvastatin—atherosclerosis	0.000274	0.0013	CcSEcCtD
Raltegravir—Tremor—Pravastatin—atherosclerosis	0.000273	0.0013	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APOA4—atherosclerosis	0.000273	0.00235	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—atherosclerosis	0.000272	0.00234	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000272	0.00129	CcSEcCtD
Raltegravir—Discomfort—Simvastatin—atherosclerosis	0.000271	0.00129	CcSEcCtD
Raltegravir—Nervous system disorder—Ezetimibe—atherosclerosis	0.000271	0.00128	CcSEcCtD
Raltegravir—Ill-defined disorder—Pravastatin—atherosclerosis	0.000271	0.00128	CcSEcCtD
Raltegravir—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00027	0.00128	CcSEcCtD
Raltegravir—Anaemia—Pravastatin—atherosclerosis	0.000269	0.00128	CcSEcCtD
Raltegravir—Skin disorder—Ezetimibe—atherosclerosis	0.000268	0.00127	CcSEcCtD
Raltegravir—Vertigo—Niacin—atherosclerosis	0.000266	0.00126	CcSEcCtD
Raltegravir—Confusional state—Simvastatin—atherosclerosis	0.000265	0.00126	CcSEcCtD
Raltegravir—Urticaria—Rosuvastatin—atherosclerosis	0.000264	0.00125	CcSEcCtD
Raltegravir—Malaise—Pravastatin—atherosclerosis	0.000263	0.00125	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EDNRA—atherosclerosis	0.000263	0.00226	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR2—atherosclerosis	0.000263	0.00226	CbGpPWpGaD
Raltegravir—Abdominal pain—Rosuvastatin—atherosclerosis	0.000262	0.00124	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000262	0.00225	CbGpPWpGaD
Raltegravir—Vertigo—Pravastatin—atherosclerosis	0.000262	0.00124	CcSEcCtD
Raltegravir—Palpitations—Niacin—atherosclerosis	0.000262	0.00124	CcSEcCtD
Raltegravir—Infection—Simvastatin—atherosclerosis	0.000261	0.00124	CcSEcCtD
Raltegravir—Cough—Niacin—atherosclerosis	0.000258	0.00123	CcSEcCtD
Raltegravir—Thrombocytopenia—Simvastatin—atherosclerosis	0.000258	0.00122	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000256	0.00122	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GHRL—atherosclerosis	0.000256	0.0022	CbGpPWpGaD
Raltegravir—Insomnia—Lovastatin—atherosclerosis	0.000255	0.00121	CcSEcCtD
Raltegravir—Cough—Pravastatin—atherosclerosis	0.000254	0.00121	CcSEcCtD
Raltegravir—Paraesthesia—Lovastatin—atherosclerosis	0.000253	0.0012	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—CCL2—atherosclerosis	0.000252	0.00217	CbGpPWpGaD
Raltegravir—Arthralgia—Niacin—atherosclerosis	0.000252	0.0012	CcSEcCtD
Raltegravir—Myalgia—Niacin—atherosclerosis	0.000252	0.0012	CcSEcCtD
Raltegravir—Hypertension—Pravastatin—atherosclerosis	0.000252	0.00119	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000251	0.00119	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCL4—atherosclerosis	0.000251	0.00216	CbGpPWpGaD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00025	0.00119	CcSEcCtD
Raltegravir—Insomnia—Ezetimibe—atherosclerosis	0.00025	0.00118	CcSEcCtD
Raltegravir—Myalgia—Pravastatin—atherosclerosis	0.000248	0.00118	CcSEcCtD
Raltegravir—Chest pain—Pravastatin—atherosclerosis	0.000248	0.00118	CcSEcCtD
Raltegravir—Arthralgia—Pravastatin—atherosclerosis	0.000248	0.00118	CcSEcCtD
Raltegravir—Paraesthesia—Ezetimibe—atherosclerosis	0.000248	0.00118	CcSEcCtD
Raltegravir—Dyspepsia—Lovastatin—atherosclerosis	0.000248	0.00117	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—KNG1—atherosclerosis	0.000248	0.00213	CbGpPWpGaD
Raltegravir—Anxiety—Pravastatin—atherosclerosis	0.000247	0.00117	CcSEcCtD
Raltegravir—Dry mouth—Niacin—atherosclerosis	0.000247	0.00117	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AGTR1—atherosclerosis	0.000246	0.00212	CbGpPWpGaD
Raltegravir—Discomfort—Pravastatin—atherosclerosis	0.000245	0.00116	CcSEcCtD
Raltegravir—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000245	0.00116	CcSEcCtD
Raltegravir—Decreased appetite—Lovastatin—atherosclerosis	0.000245	0.00116	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—atherosclerosis	0.000243	0.00209	CbGpPWpGaD
Raltegravir—Dyspepsia—Ezetimibe—atherosclerosis	0.000243	0.00115	CcSEcCtD
Raltegravir—Fatigue—Lovastatin—atherosclerosis	0.000243	0.00115	CcSEcCtD
Raltegravir—Pain—Lovastatin—atherosclerosis	0.000241	0.00114	CcSEcCtD
Raltegravir—Constipation—Lovastatin—atherosclerosis	0.000241	0.00114	CcSEcCtD
Raltegravir—Confusional state—Pravastatin—atherosclerosis	0.00024	0.00114	CcSEcCtD
Raltegravir—Decreased appetite—Ezetimibe—atherosclerosis	0.00024	0.00114	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00024	0.00114	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000238	0.00113	CcSEcCtD
Raltegravir—Asthenia—Rosuvastatin—atherosclerosis	0.000238	0.00113	CcSEcCtD
Raltegravir—Insomnia—Simvastatin—atherosclerosis	0.000238	0.00113	CcSEcCtD
Raltegravir—Fatigue—Ezetimibe—atherosclerosis	0.000238	0.00113	CcSEcCtD
Raltegravir—Infection—Pravastatin—atherosclerosis	0.000236	0.00112	CcSEcCtD
Raltegravir—Paraesthesia—Simvastatin—atherosclerosis	0.000236	0.00112	CcSEcCtD
Raltegravir—Constipation—Ezetimibe—atherosclerosis	0.000236	0.00112	CcSEcCtD
Raltegravir—Pain—Ezetimibe—atherosclerosis	0.000236	0.00112	CcSEcCtD
Raltegravir—Pruritus—Rosuvastatin—atherosclerosis	0.000235	0.00111	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APOA2—atherosclerosis	0.000235	0.00202	CbGpPWpGaD
Raltegravir—Skin disorder—Niacin—atherosclerosis	0.000235	0.00111	CcSEcCtD
Raltegravir—Hyperhidrosis—Niacin—atherosclerosis	0.000234	0.00111	CcSEcCtD
Raltegravir—Thrombocytopenia—Pravastatin—atherosclerosis	0.000233	0.00111	CcSEcCtD
Raltegravir—Feeling abnormal—Lovastatin—atherosclerosis	0.000232	0.0011	CcSEcCtD
Raltegravir—Dyspepsia—Simvastatin—atherosclerosis	0.000232	0.0011	CcSEcCtD
Raltegravir—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00023	0.00109	CcSEcCtD
Raltegravir—Hyperhidrosis—Pravastatin—atherosclerosis	0.00023	0.00109	CcSEcCtD
Raltegravir—Decreased appetite—Simvastatin—atherosclerosis	0.000229	0.00109	CcSEcCtD
Raltegravir—Feeling abnormal—Ezetimibe—atherosclerosis	0.000227	0.00108	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000227	0.00108	CcSEcCtD
Raltegravir—Diarrhoea—Rosuvastatin—atherosclerosis	0.000227	0.00108	CcSEcCtD
Raltegravir—Fatigue—Simvastatin—atherosclerosis	0.000227	0.00108	CcSEcCtD
Raltegravir—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000226	0.00107	CcSEcCtD
Raltegravir—Constipation—Simvastatin—atherosclerosis	0.000225	0.00107	CcSEcCtD
Raltegravir—Pain—Simvastatin—atherosclerosis	0.000225	0.00107	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KNG1—atherosclerosis	0.000225	0.00193	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—UTS2—atherosclerosis	0.000224	0.00193	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AGTR1—atherosclerosis	0.000224	0.00192	CbGpPWpGaD
Raltegravir—Urticaria—Lovastatin—atherosclerosis	0.000224	0.00106	CcSEcCtD
Raltegravir—Abdominal pain—Lovastatin—atherosclerosis	0.000222	0.00106	CcSEcCtD
Raltegravir—Body temperature increased—Lovastatin—atherosclerosis	0.000222	0.00106	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00022	0.00104	CcSEcCtD
Raltegravir—Dizziness—Rosuvastatin—atherosclerosis	0.00022	0.00104	CcSEcCtD
Raltegravir—Urticaria—Ezetimibe—atherosclerosis	0.000219	0.00104	CcSEcCtD
Raltegravir—Insomnia—Niacin—atherosclerosis	0.000219	0.00104	CcSEcCtD
Raltegravir—Body temperature increased—Ezetimibe—atherosclerosis	0.000218	0.00103	CcSEcCtD
Raltegravir—Abdominal pain—Ezetimibe—atherosclerosis	0.000218	0.00103	CcSEcCtD
Raltegravir—Paraesthesia—Niacin—atherosclerosis	0.000217	0.00103	CcSEcCtD
Raltegravir—Feeling abnormal—Simvastatin—atherosclerosis	0.000217	0.00103	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000217	0.00103	CcSEcCtD
Raltegravir—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000215	0.00102	CcSEcCtD
Raltegravir—Insomnia—Pravastatin—atherosclerosis	0.000215	0.00102	CcSEcCtD
Raltegravir—Somnolence—Niacin—atherosclerosis	0.000215	0.00102	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CX3CR1—atherosclerosis	0.000215	0.00185	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASR—atherosclerosis	0.000215	0.00185	CbGpPWpGaD
Raltegravir—Paraesthesia—Pravastatin—atherosclerosis	0.000214	0.00101	CcSEcCtD
Raltegravir—Dyspepsia—Niacin—atherosclerosis	0.000213	0.00101	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CX3CL1—atherosclerosis	0.000211	0.00181	CbGpPWpGaD
Raltegravir—Decreased appetite—Niacin—atherosclerosis	0.00021	0.000996	CcSEcCtD
Raltegravir—Dyspepsia—Pravastatin—atherosclerosis	0.000209	0.000994	CcSEcCtD
Raltegravir—Rash—Rosuvastatin—atherosclerosis	0.000209	0.000993	CcSEcCtD
Raltegravir—Dermatitis—Rosuvastatin—atherosclerosis	0.000209	0.000992	CcSEcCtD
Raltegravir—Urticaria—Simvastatin—atherosclerosis	0.000209	0.000992	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—EDN1—atherosclerosis	0.000209	0.0018	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Niacin—atherosclerosis	0.000209	0.00099	CcSEcCtD
Raltegravir—Abdominal pain—Simvastatin—atherosclerosis	0.000208	0.000987	CcSEcCtD
Raltegravir—Body temperature increased—Simvastatin—atherosclerosis	0.000208	0.000987	CcSEcCtD
Raltegravir—Headache—Rosuvastatin—atherosclerosis	0.000208	0.000987	CcSEcCtD
Raltegravir—Hypersensitivity—Lovastatin—atherosclerosis	0.000207	0.000983	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CCL5—atherosclerosis	0.000207	0.00178	CbGpPWpGaD
Raltegravir—Decreased appetite—Pravastatin—atherosclerosis	0.000207	0.000981	CcSEcCtD
Raltegravir—Pain—Niacin—atherosclerosis	0.000207	0.00098	CcSEcCtD
Raltegravir—Fatigue—Pravastatin—atherosclerosis	0.000205	0.000973	CcSEcCtD
Raltegravir—Pain—Pravastatin—atherosclerosis	0.000203	0.000965	CcSEcCtD
Raltegravir—Constipation—Pravastatin—atherosclerosis	0.000203	0.000965	CcSEcCtD
Raltegravir—Hypersensitivity—Ezetimibe—atherosclerosis	0.000203	0.000964	CcSEcCtD
Raltegravir—Asthenia—Lovastatin—atherosclerosis	0.000202	0.000958	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CNR2—atherosclerosis	0.0002	0.00172	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—atherosclerosis	0.0002	0.00172	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MMP3—atherosclerosis	0.000199	0.00171	CbGpPWpGaD
Raltegravir—Pruritus—Lovastatin—atherosclerosis	0.000199	0.000944	CcSEcCtD
Raltegravir—Asthenia—Ezetimibe—atherosclerosis	0.000198	0.000939	CcSEcCtD
Raltegravir—Gastrointestinal pain—Niacin—atherosclerosis	0.000198	0.000937	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—HMOX1—atherosclerosis	0.000197	0.0017	CbGpPWpGaD
Raltegravir—Nausea—Rosuvastatin—atherosclerosis	0.000197	0.000935	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PRKCG—atherosclerosis	0.000197	0.00169	CbGpPWpGaD
Raltegravir—Feeling abnormal—Pravastatin—atherosclerosis	0.000196	0.00093	CcSEcCtD
Raltegravir—Pruritus—Ezetimibe—atherosclerosis	0.000195	0.000926	CcSEcCtD
Raltegravir—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000195	0.000923	CcSEcCtD
Raltegravir—Hypersensitivity—Simvastatin—atherosclerosis	0.000194	0.00092	CcSEcCtD
Raltegravir—Diarrhoea—Lovastatin—atherosclerosis	0.000193	0.000913	CcSEcCtD
Raltegravir—Urticaria—Niacin—atherosclerosis	0.000192	0.000911	CcSEcCtD
Raltegravir—Body temperature increased—Niacin—atherosclerosis	0.000191	0.000906	CcSEcCtD
Raltegravir—Abdominal pain—Niacin—atherosclerosis	0.000191	0.000906	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EDN1—atherosclerosis	0.00019	0.00163	CbGpPWpGaD
Raltegravir—Urticaria—Pravastatin—atherosclerosis	0.000189	0.000897	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—atherosclerosis	0.000189	0.00162	CbGpPWpGaD
Raltegravir—Asthenia—Simvastatin—atherosclerosis	0.000189	0.000896	CcSEcCtD
Raltegravir—Diarrhoea—Ezetimibe—atherosclerosis	0.000189	0.000896	CcSEcCtD
Raltegravir—Abdominal pain—Pravastatin—atherosclerosis	0.000188	0.000892	CcSEcCtD
Raltegravir—Body temperature increased—Pravastatin—atherosclerosis	0.000188	0.000892	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CCL5—atherosclerosis	0.000188	0.00162	CbGpPWpGaD
Raltegravir—Pruritus—Simvastatin—atherosclerosis	0.000186	0.000883	CcSEcCtD
Raltegravir—Dizziness—Lovastatin—atherosclerosis	0.000186	0.000883	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—atherosclerosis	0.000184	0.00158	CbGpPWpGaD
Raltegravir—Dizziness—Ezetimibe—atherosclerosis	0.000183	0.000866	CcSEcCtD
Raltegravir—Diarrhoea—Simvastatin—atherosclerosis	0.00018	0.000854	CcSEcCtD
Raltegravir—Vomiting—Lovastatin—atherosclerosis	0.000179	0.000849	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PRKCG—atherosclerosis	0.000179	0.00154	CbGpPWpGaD
Raltegravir—Hypersensitivity—Niacin—atherosclerosis	0.000178	0.000845	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VWF—atherosclerosis	0.000178	0.00153	CbGpPWpGaD
Raltegravir—Rash—Lovastatin—atherosclerosis	0.000177	0.000842	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—AGER—atherosclerosis	0.000177	0.00153	CbGpPWpGaD
Raltegravir—Dermatitis—Lovastatin—atherosclerosis	0.000177	0.000841	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APOC3—atherosclerosis	0.000177	0.00152	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—atherosclerosis	0.000176	0.00152	CbGpPWpGaD
Raltegravir—Headache—Lovastatin—atherosclerosis	0.000176	0.000836	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—LDLR—atherosclerosis	0.000176	0.00151	CbGpPWpGaD
Raltegravir—Vomiting—Ezetimibe—atherosclerosis	0.000175	0.000832	CcSEcCtD
Raltegravir—Hypersensitivity—Pravastatin—atherosclerosis	0.000175	0.000832	CcSEcCtD
Raltegravir—Dizziness—Simvastatin—atherosclerosis	0.000174	0.000826	CcSEcCtD
Raltegravir—Rash—Ezetimibe—atherosclerosis	0.000174	0.000825	CcSEcCtD
Raltegravir—Dermatitis—Ezetimibe—atherosclerosis	0.000174	0.000825	CcSEcCtD
Raltegravir—Asthenia—Niacin—atherosclerosis	0.000173	0.000822	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AGT—atherosclerosis	0.000173	0.00149	CbGpPWpGaD
Raltegravir—Headache—Ezetimibe—atherosclerosis	0.000173	0.00082	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCL3—atherosclerosis	0.000172	0.00148	CbGpPWpGaD
Raltegravir—Pruritus—Niacin—atherosclerosis	0.000171	0.000811	CcSEcCtD
Raltegravir—Asthenia—Pravastatin—atherosclerosis	0.000171	0.00081	CcSEcCtD
Raltegravir—Pruritus—Pravastatin—atherosclerosis	0.000168	0.000799	CcSEcCtD
Raltegravir—Vomiting—Simvastatin—atherosclerosis	0.000167	0.000794	CcSEcCtD
Raltegravir—Nausea—Lovastatin—atherosclerosis	0.000167	0.000793	CcSEcCtD
Raltegravir—Rash—Simvastatin—atherosclerosis	0.000166	0.000787	CcSEcCtD
Raltegravir—Dermatitis—Simvastatin—atherosclerosis	0.000166	0.000786	CcSEcCtD
Raltegravir—Diarrhoea—Niacin—atherosclerosis	0.000165	0.000784	CcSEcCtD
Raltegravir—Headache—Simvastatin—atherosclerosis	0.000165	0.000782	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NCF1—atherosclerosis	0.000164	0.00141	CbGpPWpGaD
Raltegravir—Nausea—Ezetimibe—atherosclerosis	0.000164	0.000778	CcSEcCtD
Raltegravir—Diarrhoea—Pravastatin—atherosclerosis	0.000163	0.000772	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—atherosclerosis	0.000161	0.00139	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—F2—atherosclerosis	0.00016	0.00138	CbGpPWpGaD
Raltegravir—Dizziness—Niacin—atherosclerosis	0.00016	0.000758	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—atherosclerosis	0.000159	0.00137	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—PDGFB—atherosclerosis	0.000158	0.00136	CbGpPWpGaD
Raltegravir—Dizziness—Pravastatin—atherosclerosis	0.000157	0.000746	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AGT—atherosclerosis	0.000157	0.00135	CbGpPWpGaD
Raltegravir—Nausea—Simvastatin—atherosclerosis	0.000156	0.000742	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EDNRA—atherosclerosis	0.000155	0.00134	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR2—atherosclerosis	0.000155	0.00134	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CYBA—atherosclerosis	0.000155	0.00133	CbGpPWpGaD
Raltegravir—Vomiting—Niacin—atherosclerosis	0.000154	0.000729	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000153	0.00132	CbGpPWpGaD
Raltegravir—Rash—Niacin—atherosclerosis	0.000152	0.000723	CcSEcCtD
Raltegravir—Dermatitis—Niacin—atherosclerosis	0.000152	0.000722	CcSEcCtD
Raltegravir—Headache—Niacin—atherosclerosis	0.000151	0.000718	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PLAT—atherosclerosis	0.000151	0.0013	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PARP1—atherosclerosis	0.000151	0.0013	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GHRL—atherosclerosis	0.000151	0.0013	CbGpPWpGaD
Raltegravir—Vomiting—Pravastatin—atherosclerosis	0.000151	0.000718	CcSEcCtD
Raltegravir—Rash—Pravastatin—atherosclerosis	0.00015	0.000712	CcSEcCtD
Raltegravir—Dermatitis—Pravastatin—atherosclerosis	0.00015	0.000711	CcSEcCtD
Raltegravir—Headache—Pravastatin—atherosclerosis	0.000149	0.000707	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—F2—atherosclerosis	0.000145	0.00125	CbGpPWpGaD
Raltegravir—Nausea—Niacin—atherosclerosis	0.000144	0.000681	CcSEcCtD
Raltegravir—Nausea—Pravastatin—atherosclerosis	0.000141	0.00067	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—atherosclerosis	0.000139	0.0012	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KNG1—atherosclerosis	0.000133	0.00114	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR1—atherosclerosis	0.000132	0.00114	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL2—atherosclerosis	0.00013	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PLG—atherosclerosis	0.000129	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SOCS3—atherosclerosis	0.000122	0.00105	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP3—atherosclerosis	0.000118	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF2—atherosclerosis	0.000117	0.00101	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LDLRAP1—atherosclerosis	0.000114	0.000984	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APOB—atherosclerosis	0.000114	0.000979	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—atherosclerosis	0.000113	0.00097	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EDN1—atherosclerosis	0.000112	0.000963	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL5—atherosclerosis	0.000111	0.000956	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LPL—atherosclerosis	0.000109	0.000935	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLTP—atherosclerosis	0.000108	0.000925	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCG—atherosclerosis	0.000106	0.000909	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—atherosclerosis	0.000103	0.000885	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—atherosclerosis	0.000102	0.000881	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFB—atherosclerosis	9.52e-05	0.000819	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG8—atherosclerosis	9.33e-05	0.000802	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LTA4H—atherosclerosis	9.33e-05	0.000802	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGT—atherosclerosis	9.29e-05	0.0008	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LEP—atherosclerosis	9.11e-05	0.000783	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APOE—atherosclerosis	9.11e-05	0.000783	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CAV1—atherosclerosis	9.02e-05	0.000776	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APOA1—atherosclerosis	9e-05	0.000774	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ESR1—atherosclerosis	8.69e-05	0.000748	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—F2—atherosclerosis	8.59e-05	0.000739	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—atherosclerosis	8.22e-05	0.000707	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—atherosclerosis	7.87e-05	0.000677	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—INS—atherosclerosis	7.78e-05	0.000669	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL2—atherosclerosis	7.65e-05	0.000658	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1—atherosclerosis	7.52e-05	0.000647	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—atherosclerosis	7.5e-05	0.000645	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG1—atherosclerosis	7.37e-05	0.000634	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SERPINE1—atherosclerosis	7.15e-05	0.000615	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—FABP4—atherosclerosis	6.93e-05	0.000596	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LCAT—atherosclerosis	6.93e-05	0.000596	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOS3—atherosclerosis	6.82e-05	0.000587	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOA4—atherosclerosis	6.8e-05	0.000585	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP7A1—atherosclerosis	6.68e-05	0.000575	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP27A1—atherosclerosis	6.18e-05	0.000531	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL8—atherosclerosis	6.05e-05	0.000521	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALOX15—atherosclerosis	5.86e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALOX5AP—atherosclerosis	5.86e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLA2G2A—atherosclerosis	5.86e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOA2—atherosclerosis	5.86e-05	0.000504	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—atherosclerosis	5.85e-05	0.000503	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG5—atherosclerosis	5.78e-05	0.000498	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—atherosclerosis	5.75e-05	0.000495	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LPA—atherosclerosis	5.59e-05	0.000481	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—atherosclerosis	5.47e-05	0.000471	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NFKB1—atherosclerosis	5.42e-05	0.000466	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BGN—atherosclerosis	5.41e-05	0.000465	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOA5—atherosclerosis	5.36e-05	0.000461	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK8—atherosclerosis	5.32e-05	0.000458	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—atherosclerosis	5.31e-05	0.000457	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLA2G1B—atherosclerosis	5.16e-05	0.000444	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALOX5—atherosclerosis	4.98e-05	0.000428	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFA—atherosclerosis	4.91e-05	0.000423	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—atherosclerosis	4.87e-05	0.000419	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK3—atherosclerosis	4.65e-05	0.0004	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—atherosclerosis	4.51e-05	0.000388	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAMPT—atherosclerosis	4.47e-05	0.000384	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LIPC—atherosclerosis	4.44e-05	0.000382	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOC3—atherosclerosis	4.41e-05	0.000379	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LDLR—atherosclerosis	4.38e-05	0.000377	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CETP—atherosclerosis	4.28e-05	0.000368	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SCARB1—atherosclerosis	4.1e-05	0.000353	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HMGCR—atherosclerosis	3.87e-05	0.000333	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCA1—atherosclerosis	3.45e-05	0.000297	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—atherosclerosis	3.4e-05	0.000292	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—atherosclerosis	3.14e-05	0.00027	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HMOX1—atherosclerosis	2.96e-05	0.000255	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOB—atherosclerosis	2.84e-05	0.000244	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—atherosclerosis	2.76e-05	0.000237	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LPL—atherosclerosis	2.71e-05	0.000233	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPX1—atherosclerosis	2.64e-05	0.000227	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CD36—atherosclerosis	2.57e-05	0.000221	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTHFR—atherosclerosis	2.44e-05	0.00021	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARA—atherosclerosis	2.39e-05	0.000206	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AGT—atherosclerosis	2.32e-05	0.000199	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOE—atherosclerosis	2.27e-05	0.000195	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAV1—atherosclerosis	2.25e-05	0.000194	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOA1—atherosclerosis	2.24e-05	0.000193	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—atherosclerosis	2.05e-05	0.000176	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—atherosclerosis	1.98e-05	0.00017	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—INS—atherosclerosis	1.94e-05	0.000167	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—atherosclerosis	1.78e-05	0.000153	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NOS3—atherosclerosis	1.7e-05	0.000146	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—atherosclerosis	1.56e-05	0.000134	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—atherosclerosis	7.82e-06	6.73e-05	CbGpPWpGaD
